What Exenatide is
Exenatide is a GLP-1 receptor agonist derived from exendin-4 biology and used in diabetes treatment contexts.
Exenatide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it is historically important in the GLP-1 category and helps explain incretin drug development.
The useful starting point is to separate the molecule itself from the internet story around it. It is important because it helped establish the GLP-1 drug category.
Why people keep looking it up
People discuss exenatide as an early GLP-1/incretin drug.
Exenatide activates GLP-1 receptor signaling and is related to exendin-4 biology.
Exenatide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, incretin mimetic, and glucose. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
It has official clinical context, but newer weight-loss narratives should not be projected onto it without sources.
Human clinical evidence and official labeling support approved uses.
Mechanistic evidence is rooted in GLP-1 receptor activation and incretin biology.
Why this page carries the current tier: Approved drug with official labeling and human clinical evidence.
The current seed trail for Exenatide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Safety and indications should be read from official labeling rather than generalized from the peptide class.
FDA-approved exenatide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Exenatide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Exenatide is CID 45588096. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 45588096
- Formula
- C184H282N50O60S
- Molecular weight
- 4187
- InChIKey
- HTQBXNHDCUEHJF-XWLPCZSASA-N
Matched synonyms include Exenatide, 141758-74-9, Bydureon Pen, Byetta, Bydureon, Exendin 4, PT302, LY2148568.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Exenatide returns 376 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Exenatide returns 5102 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- Byetta
- Generic names
- EXENATIDE
- Routes
- SUBCUTANEOUS
- Application numbers
- NDA021773
Indications and usage. 1 INDICATIONS AND USAGE BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • BYETTA contains exenatide. Coadministration with other exenatide-containing products is not recommended. BYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS • Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including BYETTA. Discontinue if pancreatitis is suspected. ( 5.1 ) • Never share a BYETTA pen between patients, even if the needle is changed. ( 5.2 ) • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased ris...
Contraindications. 4 CONTRAINDICATIONS BYETTA is contraindicated in patients with: • A prior severe hypersensitivity reaction to exenatide or to any of the excipients in BYETTA. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with BYETTA [see Warnings and Precautions (5.7) ]. • A history of drug-induced immune-mediated thrombocytopenia from exenatide products. Serious bleeding, which may be f...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.